Incyte Corp (INCY)
53.25
+0.31
(+0.59%)
USD |
NASDAQ |
May 02, 12:48
Incyte Accounts Receivable (Quarterly): 745.53M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 745.53M |
December 31, 2023 | 743.56M |
September 30, 2023 | 657.26M |
June 30, 2023 | 637.99M |
March 31, 2023 | 623.79M |
December 31, 2022 | 644.88M |
September 30, 2022 | 618.19M |
June 30, 2022 | 682.97M |
March 31, 2022 | 562.34M |
December 31, 2021 | 616.30M |
September 30, 2021 | 516.69M |
June 30, 2021 | 438.17M |
March 31, 2021 | 397.36M |
December 31, 2020 | 481.99M |
September 30, 2020 | 356.18M |
June 30, 2020 | 420.25M |
March 31, 2020 | 351.52M |
December 31, 2019 | 308.81M |
September 30, 2019 | 276.12M |
June 30, 2019 | 302.68M |
March 31, 2019 | 244.08M |
December 31, 2018 | 307.60M |
September 30, 2018 | 247.74M |
June 30, 2018 | 316.31M |
March 31, 2018 | 220.19M |
Date | Value |
---|---|
December 31, 2017 | 266.30M |
September 30, 2017 | 198.34M |
June 30, 2017 | 169.52M |
March 31, 2017 | 244.98M |
December 31, 2016 | 148.76M |
September 30, 2016 | 131.52M |
June 30, 2016 | 129.49M |
March 31, 2016 | 101.28M |
December 31, 2015 | 114.45M |
September 30, 2015 | 86.97M |
June 30, 2015 | 75.12M |
March 31, 2015 | 69.60M |
December 31, 2014 | 57.93M |
September 30, 2014 | 109.60M |
June 30, 2014 | 47.20M |
March 31, 2014 | 46.39M |
December 31, 2013 | 35.37M |
September 30, 2013 | 33.20M |
June 30, 2013 | 27.52M |
March 31, 2013 | 28.04M |
December 31, 2012 | 70.95M |
September 30, 2012 | 16.54M |
June 30, 2012 | 13.84M |
March 31, 2012 | 13.01M |
December 31, 2011 | 6.415M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
276.12M
Minimum
Sep 2019
745.53M
Maximum
Mar 2024
519.13M
Average
539.52M
Median
Accounts Receivable (Quarterly) Benchmarks
Biogen Inc | 2.000B |
Novartis AG | 7.84B |
MorphoSys AG | 35.48M |
Illumina Inc | 734.00M |
Pfizer Inc | 11.18B |